| Literature DB >> 16787545 |
Nancy Rutherford1, Michael Mourez.
Abstract
Expressing proteins of interest as fusions to proteins of the bacterial envelope is a powerful technique with many biotechnological and medical applications. Autotransporters have recently emerged as a good tool for bacterial surface display. These proteins are composed of an N-terminal signal peptide, followed by a passenger domain and a translocator domain that mediates the outer membrane translocation of the passenger. The natural passenger domain of autotransporters can be replaced by heterologous proteins that become displayed at the bacterial surface by the translocator domain. The simplicity and versatility of this system has made it very attractive and it has been used to display functional enzymes, vaccine antigens as well as polypeptides libraries. The recent advances in the study of the translocation mechanism of autotransporters have raised several controversial issues with implications for their use as display systems. These issues include the requirement for the displayed polypeptides to remain in a translocation-competent state in the periplasm, the requirement for specific signal sequences and "autochaperone" domains, and the influence of the genetic background of the expression host strain. It is therefore important to better understand the mechanism of translocation of autotransporters in order to employ them to their full potential. This review will focus on the recent advances in the study of the translocation mechanism of autotransporters and describe practical considerations regarding their use for bacterial surface display.Entities:
Year: 2006 PMID: 16787545 PMCID: PMC1533851 DOI: 10.1186/1475-2859-5-22
Source DB: PubMed Journal: Microb Cell Fact ISSN: 1475-2859 Impact factor: 5.328
Figure 1Organization and biogenesis of autotransporters. A. The typical organization of an autotransporter (AT) comprising an N-terminal signal sequence (SS), a passenger domain and a translocation unit (TU). The passenger domain includes an N-terminal part that bears the activity of the AT and a C-terminal domain, called the autochaperone domain, which is important for efficient translocation across the outer membrane. The TU also has two distinct domains; the N-terminal region is structured as an α-helix, whereas the C-terminal region is structured as a β-barrel. B. The biogenesis of an AT has four main steps: translocation across the inner membrane, periplasmic transport, insertion into and translocation across the outer membrane and, lastly, processing of the passenger domain.
Figure 2Mechanistic models of outer membrane translocation by autotransporters. A. Hairpin model: In this model the C-terminal part of the passenger domain inserts itself as an unfolded polypeptide in the barrel of the TU, forming a hairpin. The extracellular folding of the autochaperone domain then pulls the remainder of the passenger domain. B. Threading model. This model is similar to the hairpin model but postulates that the N-terminal part of the passenger domain is inserted first, without hairpin. C. Multimeric model. In this model, multiple TUs are assembling in an oligomer forming a big central pore. Folded and unfolded polypeptides could then cross the outer membrane through this pore. D. Omp85 model. In this model, a number of periplasmic and outer membrane proteins organized around Omp85 are involved in the insertion of the TU and also the translocation across the outer membrane of the passenger domain.
Heterologous polypeptides fused to autotransporters and their surface display applications
| Name and origin | Sizea | Remarksb | |||
| CtxB, | 13 kDa | 1 disulphide, Secreted | EspP ( | Translocation studies | [69] |
| StxB, | 7.7 kDa | 1 disulphide, Secreted | MisL ( | Vaccination | [100] |
| Epitope, | 32 aas | No disulphide | Vaccination | [98, 100] | |
| Aprotinin, bovine | 62 aas | 3 disulphides, Secreted | AIDA-I ( | Translocation studies | [64] |
| OspG, | 22 kDa | Translocation studies | [84] | ||
| Sorbitol dehydrogenase, | 29 kDa | No disulphide, Cytoplasmic | Enzyme activity | [5] | |
| UreA, | 211 aas | No disulphide, Cytoplasmic | Vaccination | [99] | |
| Epitope, | 16 aas | No disulphide | Vaccination | [3] | |
| Fragment of invasin, | 58 aas | No disulphide | Study of displayed protein | [113] | |
| Adrenodoxin, bovine | 14.4 kDa | No disulphide, Secreted | Enzyme activity | [6] | |
| β- lactamase, bacterial | 286 aas | 1 disulphide, Periplasmic | Translocation studies | [62] | |
| LTB, | 11.6 kDa | 1 disulphide, Secreted | Translocation studies | [68] | |
| CtxB, | 13 kDa | 1 disulphide, Secreted | Translocation studies | [114] | |
| Synthetic protease inhibitor | 15 aas | No disulphide | Random screening | [110] | |
| MalE, | 366 aas | No disulphide, Periplasmic | Translocation studies | [74] | |
| Lipase, | 181 aas | Secreted | EstA ( | Enzyme activity | [101] |
| Lipase, | 214 aas | Secreted | Enzyme activity | [101] | |
| Lipase, | 613 aas | Secreted | Enzyme activity | [101] | |
| β- lactamase, bacterial | 286 aas | 1 disulphide, Periplasmic | EstA ( | Translocation studies | [108] |
| FimH lectin domain, | 177 aas | 1 disulphide, Secreted, | Ag43 ( | Translocation studies | [106] |
| Various epitopes | 12–14 aas | No disulphide | Ag43 ( | Vaccination | [106] |
| MalE, | 366 aas | No disulphide, Periplasmic | IcsA ( | Translocation studies | [63] |
| PhoA, | 471 aas | 2 disulphides, Periplasmic | Translocation studies | [63] | |
| Pseudo-azurin, | 123 aas | No disulphide, Periplasmic | Ssp ( | Translocation studies | [112] |
| Fos and Jun leucine zipper domains | 8 kDa | No disulphide, Intracellular | IgA protease ( | Translocation studies | [115] |
| Single-chain antibody (ScFv) | 30 kDa | 2 disulphides, Secreted | 440 aas/1505 aas | Translocation studies | [66] |
| Single-chain antibody (ScFv) | 30 kDa | 2 disulphides, Secreted | Drug delivery | [116] | |
| CtxB, | 13 kDa | 1 disulphide, Periplasmic | Translocation studies | [60] | |
| β- lactamase/trypsin inhibitor | 314 aas | 4 disulphide, Periplasmic | Random screening | [9] | |
| Metallothionein, murine | 7 kDa | No disulphide, Intracellular | Enzyme activity | [7] | |
a: sizes are given as molecular weights (in Daltons) or as a number of aminoacids (aas); b: When known, the number of disulphide bridges normally found in the displayed polypeptides are indicated, as well as an indication of their original cellular localization. c: Unless otherwise indicated, all fusions were made to a C-terminal fragment of an AT, the name of the AT is provided, along with the bacterial species from which it originates and the lengths of the fragment and full length protein. d: The polypeptides were inserted as "sandwich fusions" in the full-length sequence of Ag43.